Get the latest tech news
Amgen to Build Generative AI Models for Drug Discovery
Amgen will build AI models trained to analyze one of the world’s largest human datasets on an NVIDIA DGX SuperPOD, a full-stack data center platform.
Freyja will be used to build a human diversity atlas for drug target and disease-specific biomarker discovery, providing vital diagnostics for monitoring disease progression and regression. “Models trained in BioNeMo can advance drug discovery on multiple fronts,” said Marti Head, executive director of computational and data sciences at Amgen. By adopting DGX SuperPOD, Amgen is poised to gain unprecedented data insights with the potential to change the pace and scope of drug discovery.
Or read this on r/technology
